This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1187 entries already.
BioInvent has successfully carried out a directed share issue of approximately SEK 300 million (approximately USD 28.3 million). A number of international and Swedish investors participated, including new investors such […]
Immunocore sells around 3.7m shares in a private placement with a 20% discount and gets USD140m to advance its pipline.
A current Nature study specifies the most competitive health biotech sectors worldwide and puts Switzerland at the top, Sweden second and the USA third. Does the new math convince?
GlaxoSmithKline (GSK), one of the UKs large pharma player, has voted to spin-off its consumer healthcare business into a new company called Haleon. Shareholders gave the go-ahead for GSK to demerge on […]
European Medicines Agency (EMA) has accepted the application for biosimilar natalizumab, a proposed biosimilar to Tysabri® (Biogen) in the indication of Multiple Sclerosis (MS).
Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (38.4 million), bringing the total Series B […]
Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was […]
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
The European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused on bio-based […]
Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.